Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional

BIBTEX RIS

“I’m looking through you”: What consumers and manufacturers need to know about non-invasive diagnostic tests for endometriosis

2023; Elsevier BV; Volume: 2; Linguagem: Inglês

10.1016/j.jeud.2023.100031

2949-8384

Paola Viganò, Paolo Vercellini, Edgardo Somigliana, Charles Chapron, Felice Petraglia, Linda G. Griffith, Michael D. Mueller, Dan C. Martin, Annemiek W. Nap, Andrea Romano, Fernando M. Reis, Francisco Carmona, Katherine A. Burns, Hugh S. Taylor, Piétro Santulli, М. Canis, Philippe R. Koninckx, Sun‐Wei Guo,

Uterine Myomas and Treatments

Consequences of the shift from the use of non-invasive testing for diagnosis to screening purposes • As the high-throughput screening and sequencing become increasingly faster and affordable, that there will be a swell of commercial non-invasive diagnostic tests for endometriosis in the coming years to fill the void. • Overdiagnosis is common when introducing a novel diagnostic test and overdiagnosis leads to overtreatment that provides, by definition, no benefit at all but that can cause harm and incur expenses. • The shift from the use of non-invasive testing for diagnostic purposes (i.e.use in symptomatic women) to screening purposes (i.e., use in asymptomatic women) is very likely. • In presence of pain symptoms, endometriosis must be promptly suspected and clinically diagnosed regardless of imaging findings and non-invasive diagnostic testing.